SIMCERE PHARMA Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

SIMCERE PHARMA announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute of Materia Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinical Trial Approval issued by the National Medical Products Administration  in China, and is proposed for post-exposure prophylaxis for close contacts of individuals who test positive for SARS-CoV-2.